This was the stock's second consecutive day of gains.

Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Charles River (CRL) to $184 from $220 and keeps an Equal Weight rating ...

Contract researcher Charles River Laboratories, which has been slashing costs as it faces financial headwinds, plans to ...

Charles River is shuttering its pathology facility in Durham, North Carolina, after determining the site “is not a strategic ...

The outlook for Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International ...

Shares of Charles River Laboratories International Inc. CRL shed 1.91% to $161.62 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX ...

Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William ...

The Convention on International Trade in Endangered Species of Wild Fauna and Flora, or CITES, Standing Committee has voted to defer the ...

Flagship Harbor Advisors LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Charles River Laboratories (NYSE:CRL) lost ~12% in the premarket on Tuesday after the contract research organization said its 2025 revenue on an organic basis is expected to decline at a similar ...